Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cellsSumati Gupta, Sunil Sharma, Kelly Doyle et al.|Oncotarget|2018Cited by 27
Histone Deacetylase Inhibition Has Targeted Clinical Benefit in <i>ARID1A</i> -Mutated Advanced Urothelial CarcinomaSumati Gupta, Sunil Sharma, Daniel J. Albertson et al.|Molecular Cancer Therapeutics|2018Cited by 24
Clinical and translational investigation of pan-HDAC inhibition in advanced urothelial carcinoma (UC).Sumati Gupta, Neeraj Agarwal, Daniel J. Albertson et al.|Journal of Clinical Oncology|2017Cited by 2
Supplemental figure 4 from Histone Deacetylase Inhibition Has Targeted Clinical Benefit in <i>ARID1A</i>-Mutated Advanced Urothelial CarcinomaSumati Gupta, Sunil Sharma, Daniel J. Albertson et al.|Unknown|2023Cited by 0